Relmada Therapeutics: Funding, Investors & Team (Oct 2026)
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults.()
Relmada Therapeutics has raised $310M across 2 funding rounds on record, the most recent an undisclosed round of $160M announced in Mar 2026.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Relmada Therapeutics Company Profile and Key Stats
Latest funding round on record: Mar 2026.
Relmada Therapeutics Funding Rounds
Relmada Therapeutics raised $150M in a Post-IPO Equity announced in Dec 2021.
4.3 years later, an undisclosed round of $160M was announced in Mar 2026.
Relmada Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Relmada Therapeutics Funding Compared to Other Biotechnology Startups
Relmada Therapeutics' latest round of $160M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Relmada Therapeutics in Biotechnology and New York
Companies Similar to Relmada Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Relmada Therapeutics Funding FAQs
What does Relmada Therapeutics do?
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults.()
How much funding has Relmada Therapeutics raised?
Relmada Therapeutics has raised $310M across 2 rounds on record. The most recent is an undisclosed round of $160M announced in Mar 2026.
When did Relmada Therapeutics last raise funding?
Relmada Therapeutics' most recent funding round on record is an undisclosed round of $160M, announced in Mar 2026.
Who is the CEO of Relmada Therapeutics?
Sergio Traversa is listed as CEO at Relmada Therapeutics.
Where is Relmada Therapeutics headquartered?
Relmada Therapeutics is based in New York, United States.
How many employees does Relmada Therapeutics have?
Relmada Therapeutics is in the 11-50 employee band.
How does Relmada Therapeutics' funding compare to other Biotechnology startups?
Relmada Therapeutics' latest round of $160M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Relmada Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Relmada Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.